Protocol PRT1419-03: A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies.
A study of investigational MCL1 inhibitor PRT1419 given intravenously to treat patients with Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS).
Prior treatment requirements:
AML: Eligible patients are relapsed, refractory, or intolerant to all available therapies with known benefit.
CMML: Eligible patients must have failed at least 4-6 cycles of treatment with a hypomethylating agent.
MDS: Eligible patients must be relapsed or refractory to approved therapies, including at least 4-6 cycles of a hypomethylating agent.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.